Management of Glycemia in Diabetic Patients with Diabetic Kidney Disease
Liu Fang,Fu Ping
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20132042
IF: 6.133
2014-01-01
Chinese Medical Journal
Abstract:Diabetes has emerged as a worldwide epidemic chronic disease with rapidly increasing prevalence. In 2011, the global prevalence of diabetes among adults was 6.4%, affecting 366 million adults and will rise to 552 million adults by 2030.1 According to the latest epidemiological data in a nationally representative sample of 98 658 Chinese adults in 2010, the prevalence of total diabetes has already reached 11.6%, affecting 113.9 million Chinese adults.2 Diabetes increases the risk of macrovascular and microvascular complications. One-third of the patients with diabetes usually present with chronic kidney involvement. Diabetic kidney disease (DKD), one of the most common microvascular complications of diabetes, acts as the leading cause of end stage renal disease (ESRD) in developed countries accounting for approximately 50% of all cases of patients requiring dialysis and as the second leading cause of that in China. Albuminuria and impaired glomerular filtration rate (GFR) lead to ESRD and increase the risks of cardiovascular morbidity and mortality in DKD patients. Renal replacement therapy in ESRD imposes an increasing economic burden on national health-care systems worldwide. Data from China show that only 25.8% of patients with diabetes received treatment for diabetes and only 39.7% of those treated had adequate glycemic control.2 As is known, inadequate glycemic control is closely associated with poor outcomes of diabetes. Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS) demonstrated the benefits of intensive glycemic control on a continuous reduction of cardiovascular risks, decreased rate of albuminuria, and decline in GFR among the patients with both types 1 and 2 diabetes mellitus (DM), particularly in early stages.3–7 Likewise, recent results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) showed the benefit of intensive glycemic control on reduction of risks of ESRD, microalbuminuria, and macroalbuminuria.8 Intensified glucose lowering treatment has been shown to be superior to standard of care in reducing the levels of microalbuminuria in patients with microalbuminuria.9 These findings imply that good glycemic control may be more crucial in preventing or delaying the development and progression of DKD than blood pressure and lipid control.10,11 Thus, ideal glycemic targets with appropriate antidiabetic agents are recommended according to age, duration of diabetes, coexisting cardiovascular disease, presence or absence of other comorbidities, the level of GFR with or without albuminuria, and the risk of hypoglycemia. On the other hand, inappropriate glycemic control has been also identified as closely associated with an increased risk for hypoglycemia, cardiovascular events, and all-cause mortality of diabetic patients with DKD. With the decline in renal function, glycemic control in patients with DKD becomes more complex and unique than general diabetic patients. Therefore, this review aims to summarize the evidence and depict recommended management strategies for glycemic control in diabetic patients with DKD. Special glycemic target for patients with DKD As recommended by the American Diabetes Association (ADA), glycemic targets of fasting blood glucose <6.1 mmol/L, 2 hours postprandial blood glucose <8.0 mmol/L, and HbA1c <7% for general adult population with DM are reasonable.12 While the benefits of intensive glycemic therapy for people with diabetes and the glycemic targets for general DM adult population have been well established, special considerations of the special HbA1c target for particular patients with chronic comorbidities and complications should be taken, particularly among individuals who have a reduced GFR.13 As glycemic goals are approached, the risk of larger glycemic variability and hypoglycemia increases due to many predisposing factors, including renal insufficiency,14 aging, special pharmacokinetics, irregular meal patterns, and infrequent self-monitoring of blood glucose. The risk of hypoglycemia is increased in patients with advanced chronic kidney disease (CKD) (CKD stages 4 and 5) for three reasons: (1) decreased clearance of insulin and some of the antidiabetic oral agents, (2) impaired renal gluconeogenesis with the decline in kidney function, and (3) decreased reabsorption of glucose.15,16 As about one-third of insulin degradation is carried out by the kidneys, the impairment of kidney function is associated with a prolonged half-life of insulin and oral diabetic drugs, necessitating the regulation of therapy regimen and change in drug dosing and intensive monitoring of blood glucose. So, severe hypoglycemia raises safety concerns that may be of particular relevance for patients with decreased kidney function when formulating treatment strategies.17 Aiming for HbA1c level of <7.0% still remains the general target for good glucose control in general diabetic patients, even lower HbA1c particularly in the setting of newly diagnosed diabetes in relatively young individuals without significant comorbidities and chronic complications. Still today, the guidelines to give advice on the management of glycemia or the use of specific antidiabetic drugs in patients with comorbidity are scarce. Until further data are available, the personalized and specific approach for glucose management is recommended in people with DKD. The KDOQI Clinical Practice Guideline for Diabetes and Chronic Kidney Disease in 2012 gave advice that a target HbA1c of ˜7.0% to prevent or delay the progression of the microvascular complications of diabetes, including DKD, is recommended; however, an HbA1c target of <7.0% is not recommended in patients at risk of hypoglycemia, particularly those being treated with insulin or sulfonylureas and those with substantially decreased eGFR (CKD stages 4 and 5), and a target HbA1c >7.0% in patients with advanced CKD, or limited life expectancy is suggested.18,19 Recently, the Italian Association of Diabetologists (Associazione Medici Diabetologi, AMD) has already recognized the importance of the personalized treatment plan for people with type 2 diabetes and developed the therapeutic algorithms, taking consideration of several variables such as aging, efficacy, potential side effects of antidiabetic drugs, hypoglycemic risk, and comorbidities.20 It recommended a target HbA1c of 7.0%-8.0% for the elderly (>70 years) patients with the presence of macrovascular complications whose eGFR should be carefully evaluated. Thus, the flexible regimens of treatment with antidiabetic drugs and setting the individualized glycemic goals are strongly recommended.21 Iitegrated management of glycemia in diabetic patients with DKD Lifestyle modification Multimodal approaches including lifestyle modifications and multidrug therapy will be required to optimize the control of hyperglycemia. Lifestyle modification is considered fundamental of diabetes care,22 including weight loss,23 lower levels of sitting time, low-calorie diabetic diet in obese,24 alcohol, smoking cessation, and physical activity.25,26 Dietary regimens should also be considered in the management of patients with DKD. The nutritional status of patients with DKD varies widely from obesity to malnutrition according to the type of diabetes, the stages of the renal disease, the severity of kidney function, and the comorbidities. In general, the Western-style diet with highly processed and refined foods and high contents of sugars, salt, fat, and protein from red meat has been recognized as the major contributor to the development of obesity-related diseases including type 2 diabetes, hypertension, cardiovascular diseases, and kidney diseases. For general population with diabetes, the total calories recommended is lower than 30 kcal/kg of ideal body weight per day. For body weight loss of the obesity patients, high-calorie and low-fat diet are beneficial for glucose control and reduction in urinary albumin excretion.27 For the pre-dialysis patients with DKD, the high-quality low-protein diet (0.6 g·kg−1·d−1) withdrawing red meat was found reducing hyperglycemia and proteinuria, retarding progression of DKD, and improving the outcome of the patients, and ketoanalogs supplementation to low-protein diet is beneficial for maintaining the nutritional status and avoiding malnutrition.28–32 During the first 3 months after the initiation of low-protein diet treatment, the nutritional status indicators, such as calculation of calories, protein intake, body mass index, arm muscle circumference, skin fold thickness, serum albumin, prealbumin, subjective global nutritional assessment, and protein decomposition rate, should be tested once a month, and then once every 2–3 months. Oral medications Oral antidiabetic drugs (OADs) are the mainstay of therapy for most type 2 diabetes. Though there was insufficient and low-quality evidence on the effectiveness of individual OADs on delaying the progression of DKD, for a majority of patients with early DKD, OADs with low nephrotoxicity, but not insulin therapy, are preferred at first. Of the OADs currently available for the treatment of type 2 diabetes, the sulfonylureas and metformin are generally safe and well tolerated. In patients with chronic renal insufficiency, however, intensive care must be exercised in using many of these drugs, as accumulation either of the active drugs or of active metabolites can lead to serious adverse effects such as hypoglycemia or lactic acidosis with metformin. Sulfonylureas The sulfonylurea drugs are the earliest and most widely used antidiabetic agents which stimulate the secretion of insulin of islet β cells and increase insulin sensitivity of the peripheral tissues. To a greater or lesser degree, they are metabolized in the liver to a variety of active or inactive compounds which are excreted by the kidneys. Varying amounts of parent compound may depend on renal elimination and the progressive fall of kidney function results in decreased clearances of the sulfonylureas or their active metabolites, necessitating a decrease in drug dosing to avoid hypoglycemia. Avoiding first-generation sulfonylureas such as chlorpropamide, tolazamide, and tolbutamide is recommended by KDOQI in 2012 for diabetes with CKD.18 Secondgeneration sulfonylureas such as glyburide have long half-life and are more likely to cause significant hypoglycemia as the metabolism of these drugs can lead to the accumulation of either the parent drug or the active metabolite in the presence of renal insufficiency, thus they are suggested not to be used for diabetes with CKD. However, glipizide, gliclazide, and gliquidone are found much less likely to cause hypoglycemia as the metabolism is maintained in patients with hepatic insufficiency and accumulation does not take place in patients with renal insufficiency, and their metabolites are either inactive or have minimal hypoglycemic potency. In particular, gliquidone was recommended as the first choice for DKD patients for its special metabolism and the route of excretion of metabolites by the kidneys.33 And glipizide or glinide is the preferred agent as it does not have active metabolites and does not increase the risk of hypoglycemia in patients with CKD. As the recommendation of the use of second-generation sulfonylureas by the ADA and European Association for the Study of Diabetes, conversion from glyburide to glipizide was found to be associated with an increase in HbA1c, but the reduced incidence of hypoglycemia was found in patients with a calculated creatinine clearance <50 ml·min−1·1.73 m−2.34 As mentioned above, a non-sulfonylurea insulin secretagogue such as repaglinide does not increase the risk of accumulation of active metabolite in patients with renal dysfunction, which is considered as a good alternative for sulfonylurea starting with a dose of 0.5 mg with each meal and titrated upward with caution when GFR is <30 ml·min−1·1.73 m−2. Biguanides The biguanides drugs withdrawn from the market have been widely used as antidiabetic agents from the 1950s. Metformin as monotherapy does not cause hypoglycemia and is recommended as first-line antidiabetic agent for obese type 2 diabetic patients by almost all guideline committees worldwide. The mechanism by which metformin exerts its antihyperglycemic effects is mediated by inhibiting the absorption of glucose in intestine, reducing hepatic glucose production and glucose output, promoting the uptake of glucose in the peripheral tissues, increasing the insulin sensitivity, and improving insulin resistance. Nearly 90% metabolites of the biguanides drugs are excreted by the kidneys. Phenformin is no longer used. During the past half century, the role of metformin in diabetic therapeutic history has experienced ups and downs in the therapy of type 2 diabetes. Until 1995, FDA approved the reuse of metformin, but it was not recommended to be used in patients with serum creatinine levels >1.5 mg/dl (132 μmol/L) in men and 1.4 mg/dl (123 mol/L) in women or eGFR <60 ml·min−1·1.73 m−2 as KDOQI recommendations in 2012, although the restriction to the creatinine cutoffs or GFR cutoff of <60 ml·min−1·1.73 m−2 is still controversial. The pharmacokinetics of metformin revealed the clearance of metformin decreases by about 75% when the GFR is <60 ml·min−1·1.73 m−2 and without further change when the GFR declines to 30 ml·min−1·1.73 m−2.35 In the patients continuing to receive metformin with GFR levels within the range of 30–60 ml·min−1·1.73 m−2, lactic acidosis is still rare even in the presence of comorbidities such as congestive heart failure, chronic obstructive pulmonary disease, and liver disease.36 Considering the clinical benefits of metformin,37–39 the use of metformin is reevaluated when GFR is <45 ml·min−1·1.73 m−2 and stopped when <30 ml·min−1·1.73 m−2; so the exact GFR cutoff for the use of metformin in DKD was adopted as 30 ml·min−1·1.73 m−2 by the British National Formulary40,41 and Japan.42 Other oral medications Thiazolidinediones act as insulin sensitizer by reversing insulin resistance and improving insulin sensitivity via the activation of the transcription factor peroxisome proliferator-activated receptor-γ (PPAR-γ). Thiazolidinediones such as pioglitazone and rosiglitazone are widely prescribed clinically as they have good glycemic effect without hypoglycemia both as a monotherapy and in combination with other antiglycemic agents, and they can be used in CKD patients because they are metabolized by the liver. However, the side effects such as fluid retention, weight gain, risk of congestive heart failure,43 and myocardial infarction44,45 limit their use in advanced heart failure and CKD. In 2010, the FDA restricted the use of rosiglitazone based on information linking the medication to increased cardiovascular events.46 Acarbose, an α-glucosidase inhibitor, is only minimally absorbed, but serum concentrations of the drug and its metabolites increase significantly with reduced kidney function. Although no adverse effects have been reported, its use in patients with a GFR<30 ml·min−1·1.73 m−2 is not recommended.18 Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin, saxagliptin, and linagliptin improve the HbA1c level by decreasing the breakdown of the incretin hormones, such as glucagon-like peptide 1 (GLP-1). They can be used both as monotherapy and in combination with others. In patients with renal insufficiency, the drug dosage adjustment is necessary except for linagliptin.47 Sodium-glucose co-transporter 2 (SGLT2) inhibitors such as dapagliflozin act as antihyperglycemic agents by increasing renal glucose excretion. Additionally, they may have a diuretic-like capacity to lower blood pressure and body weight in addition to beneficial effects on glycemic control.48 Evidence based on the use of SGLT2 inhibitors in patients with renal insufficiency is lacking. Insulin With the progression of diabetes and β-cell dysfunction, most patients eventually require insulin injection to maintain ideal glucose level. In healthy population, there are two aspects of insulin secretion: (1) basal insulin secretion by pancreatic β cells that secrete continuously to maintain steady glucose levels during the fasting periods, and (2) additional insulin secretion with meal in which insulin is rapidly released in an initial first-phase spike in acute response to a meal, followed by prolonged insulin secretion that returns to basal levels after 2–3 hours, to suppress hepatic glucose production and to increase glucose transport into muscle, fat, and liver.49–51 Thus, the insulin regimens we select are used to try to mimic the normal physiologic insulin secretion pattern and usually include long-acting basal insulin for between-meal and nocturnal glycemic control, together with preprandial bolus injections of rapid-acting insulin for meal-stimulated glycemic increases. During the development of diabetes, with the appearance of β-cell dysfunction and chronic complications, normal physiologic insulin secretion is progressively disrupted, and insulin therapy, either monotherapy or coadministration with oral antidiabetic agents, is ultimately required for glycemic control. Particularly, few OADs can be used in patients with ESRD, which makes them much more important for insulin therapy. But insulin requirement and appropriate dosing may tend to change due to the metabolic alteration of insulin with the loss of kidney function, because uremia and dialysis make glucose control complicated by affecting the secretion, clearance, insulin sensitivity, and peripheral tissue sensitivity of insulin.52 As 30%-80% insulin is eliminated by renal excretion, insulin levels are higher in patients with overt DKD. Moreover, the metabolic response to regular insulin is reduced.53 Thus, the diabetic patients treated with insulin, particularly those who have low eGFR or on hemodialysis (HD) with glucosefree dialysates, are at high risk of hypoglycemia, and it is suggested to alter the insulin regimen and decrease the dosage of insulin. For the rapid-acting, long-acting, and premixed intermediate-acting insulin used in patients with renal dysfunction, dosing adjustment should be considered. Reduction in dosing by 25% when GFR is 10–50 ml·min−1·1.73 m−2 and by 50% when GFR <10 ml·min−1·1.73 m−2 is recommended.52 To mimic the normal physiologic insulin secretion pattern and lower the risk of hypoglycemia for patients with renal insufficiency, there are two insulin therapy regimens with analogs: (1) one dose of basal long-acting insulin analog at bedtime combined with three doses of rapid-acting insulin analog preprandially and (2) a premixed insulin analog in one or two injections. Though there are limited data in the literature concerning insulin analog usage in diabetic ESRD patients, compared with the latter regimen, the former is found to provide better glycemic control with a lower risk of hypoglycemia.54,55 Rapid-acting analogs, acting within minutes and peaking in about 1 hour, are found being absorbed faster than regular insulin in patients with renal failure,56 and long-acting analogs provide a relatively peakless, continuous release over approximately 16–24 hours.57 While neutral protamine hagedorn (NPH) insulin is the traditional basal insulin, the most recent consensus statement from the American Association of Clinical Endocrinologists and the American College of Endocrinology strongly recommended NPH insulin to be superseded by synthetic insulin analogs.58 Management of glycemia in diabetic patients on renal replacement therapy Hemodialysis (HD) and peritoneal dialysis (PD) are wellestablished forms of therapy for ESRD patients requiring renal replacement therapy (RRT). However, there is lack of information about the management of glycemic control in patients with diabetes on HD and PD. Poor glycemic control is also shown as an independent predictor of mortality, both for cardiovascular and noncardiovascular mortality, and shortens survival in diabetic patients with ESRD.59–61 Although HbA1c measurement can be confounded in the uremic milieu, it should be a reasonable measure of glycemic control even in dialysis patients, as long as they are not overtly anemic.62,63 Other measures of long-term glycemic control in uremia include glycated fructosamine64 and glycated albumin.65,66 However, glucose metabolism of patients on dialysis is postulated to present complexity and to be multifactorial. On the one hand, glycemic control improves with the decline in kidney function, loss of residual renal function, and the initiation of dialysis therapy, while even leading spontaneously to hypoglycemia, requiring cessation of insulin or other diabetic medications, which was called "burnt-out diabetes."62 Approximately one-third of all diabetic HD patients in the United States have low HbA1c below 6%, not needing insulin injection.67 Their HbA1c levels shift to normal range and serum glucose goes into normal or even low ranges and they often suffer from the risk of hypoglycemia. On the other hand, the uremic state alters glucose homeostasis in patients with CKD; even individuals with CKD but without DM can show mild fasting hyperglycemia and insulin resistance.68 The mechanism of increased insulin resistance in patients with CKD is also not fully understood. With the decline in renal function, insulin resistance and deficiency may coexist and contribute to the complex changes of insulin metabolism. Uremic toxins are shown to be linked with the abnormal insulin metabolism, which could be improved by the initiation of dialysis therapy.69–72 PD therapy has been shown to improve insulin sensitivity superior to HD73 or similar to HD therapy74 in nondiabetic patients with ESRD. However, some studies showed that long-term PD could result in significantly greater glucose intake from dialysate, particularly if hypertonic (4.25% glucose) dialysis solution is required to achieve ultrafiltration (UF) goals, which implied the high glucose content of PD solutions might be responsible for insulin resistance. The abnormality of glucose metabolism makes the management of glycemia in diabetic patients on PD difficult. A low-glucose dialysis regimen has been shown to improve metabolic indices in diabetic patients receiving PD but may be associated with an increased risk of extracellular fluid volume expansion.75 Icodextrin has been shown to improve peritoneal UF and fluid control and reduce the burden of glucose overexposure, thereby facilitating metabolic control.76 Conclusions Diabetic patients with renal insufficiency are a special group when considering glycemia management. Selection of appropriate antidiabetic regimens and individualization of therapy can help patients achieve recommended glycemic goals while minimizing hypoglycemia. Impairment of renal function is an important comorbidity to be considered when selecting antidiabetic drugs.13 The phenomenon of "burntout diabetes" is common in patients on HD; however, longterm PD with high glucose content of PD solutions results in abnormal glucose metabolism. Specific researches on dialysis are needed in the future.